Cart
sales@molnova.com
Lapatinib ditosylate monohydrate
CAS No. 388082-78-8
Lapatinib ditosylate monohydrate ( —— )
Catalog No. M14336 CAS No. 388082-78-8
Lapatinib ditosylate is an anti-Y drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung Y.
Purity : >98%(HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 50MG | 43 | In Stock |
|
| 100MG | 58 | In Stock |
|
| 200MG | 86 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLapatinib ditosylate monohydrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionLapatinib ditosylate is an anti-Y drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung Y.
-
DescriptionLapatinib ditosylate is an anti-Y drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung Y.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR; HER2/ErbB2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number388082-78-8
-
Formula Weight943.47
-
Molecular FormulaC29H26ClFN4O4S·2(C7H8O3S)·H2O
-
Purity>98%(HPLC)
-
SolubilitySoluble in DMSO
-
SMILESO.CC1=CC=C(C=C1)S(O)(=O)=O.CC1=CC=C(C=C1)S(O)(=O)=O.CC1=CC=C(C=C1)S(O)(=O)=O.CC1=CC=C(C=C1)S(O)(=O)=O.CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1.CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Rusnak DW, et al. Mol Y Ther, 2001, 1(2), 85-94.
molnova catalog
related products
-
Nimotuzumab
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
-
Afatinib dimaleate
An irreversible, dual EGFR/HER2 inhibitor with IC50 of 0.5/0.4/10/14 nM for wt EGFR/EGFR L858R/EGFR L858R+T790M/HER2 respectively.
-
HKI-357
HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 (IC50s: 34 nM and 33 nM). HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.
